Peijia Medical Ltd (HKG: 9996), a leading medical device company, has announced the completion of its first compassionate use case utilizing the Taurus Trio transcatheter aortic valve replacement (TAVR) system in Hong Kong. This milestone marks a significant step in the application of the company’s advanced cardiovascular technology in the region.
Taurus Trio TAVR System and Its Clinical Progress
The Taurus Trio TAVR system, designed to treat severe symptomatic aortic valve regurgitation, has reached a pivotal clinical milestone. Patient enrollment for a China multi-center regulatory study was completed in January 2024, with follow-up evaluations currently in progress. This regulatory study is crucial for the system’s approval and subsequent commercialization in the Chinese market, highlighting Peijia Medical’s commitment to advancing cardiac care through innovative solutions.
Compassionate Use and Clinical Impact
The first compassionate use case in Hong Kong demonstrates the potential of the Taurus Trio TAVR system to provide immediate relief to patients in need. Compassionate use programs are essential for making new medical technologies available to patients who may not otherwise have access, particularly in cases where traditional treatment options have been exhausted or are deemed inadequate.-Fineline Info & Tech
Leave a Reply